[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0413616B8 - 2,4-pirimidinadiaminas, seus usos, e composição farmacêutica - Google Patents

2,4-pirimidinadiaminas, seus usos, e composição farmacêutica

Info

Publication number
BRPI0413616B8
BRPI0413616B8 BRPI0413616A BRPI0413616A BRPI0413616B8 BR PI0413616 B8 BRPI0413616 B8 BR PI0413616B8 BR PI0413616 A BRPI0413616 A BR PI0413616A BR PI0413616 A BRPI0413616 A BR PI0413616A BR PI0413616 B8 BRPI0413616 B8 BR PI0413616B8
Authority
BR
Brazil
Prior art keywords
pyrimidinediamines
pharmaceutical composition
treatment
fak
zap
Prior art date
Application number
BRPI0413616A
Other languages
English (en)
Inventor
Garcia-Echeverria Carlos
Karanewsky Donald
Kawahara Eiji
Chopiuk Greg
Umemura Ichiro
Jiang Jiqing
Masuya Keiichi
Matsuura Naoko
Schiander Gray Nathanael
Ohmori Osamu
Ding Qiang
Zhang Qiong
Steensma Ruo
Miyake Takahiro
Kanazawa Takanori
Wan Yongqin
Original Assignee
Irm Llc
Novartis Ag
Novartis Int Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34196260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0413616(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0319227A external-priority patent/GB0319227D0/en
Priority claimed from GB0322370A external-priority patent/GB0322370D0/en
Application filed by Irm Llc, Novartis Ag, Novartis Int Pharmaceutical Ltd filed Critical Irm Llc
Priority to BR122019017579A priority Critical patent/BR122019017579B8/pt
Publication of BRPI0413616A publication Critical patent/BRPI0413616A/pt
Publication of BRPI0413616B1 publication Critical patent/BRPI0413616B1/pt
Publication of BRPI0413616B8 publication Critical patent/BRPI0413616B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Manufacturing & Machinery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Ceramic Engineering (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)

Abstract

2,4-pirimidinadiaminas úteis no tratamento de doenças neoplásicas, distúrbios inflamatórios e distúrbios do sistema imunológico. novos derivados de pirimidina de fórmula (i) onde r é selecionado de c16-10 arila, c5-10 heteroarila, c3-12 cicloalquila e c3-10 heterocicloalquila; r0 - r6 são como aqui descritos; e seu uso para a produção de um medicamento para o tratamento ou a prevenção de uma doença que responde à inibição de fak e/ou alk e/ou zap-70 e/ou igf-ir.
BRPI0413616A 2003-08-15 2004-08-13 2,4-pirimidinadiaminas, seus usos, e composição farmacêutica BRPI0413616B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019017579A BR122019017579B8 (pt) 2003-08-15 2004-08-13 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0319227A GB0319227D0 (en) 2003-08-15 2003-08-15 Organic compounds
GB0322370A GB0322370D0 (en) 2003-09-24 2003-09-24 Organic compounds
PCT/EP2004/009099 WO2005016894A1 (en) 2003-08-15 2004-08-13 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

Publications (3)

Publication Number Publication Date
BRPI0413616A BRPI0413616A (pt) 2006-10-17
BRPI0413616B1 BRPI0413616B1 (pt) 2020-04-28
BRPI0413616B8 true BRPI0413616B8 (pt) 2021-05-25

Family

ID=34196260

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019017579A BR122019017579B8 (pt) 2003-08-15 2004-08-13 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica
BRPI0413616A BRPI0413616B8 (pt) 2003-08-15 2004-08-13 2,4-pirimidinadiaminas, seus usos, e composição farmacêutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122019017579A BR122019017579B8 (pt) 2003-08-15 2004-08-13 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica

Country Status (32)

Country Link
US (2) US7893074B2 (pt)
EP (2) EP2287156B1 (pt)
JP (2) JP4607879B2 (pt)
KR (1) KR100904570B1 (pt)
AR (1) AR045458A1 (pt)
AT (1) ATE542801T1 (pt)
AU (2) AU2004264382A1 (pt)
BR (2) BR122019017579B8 (pt)
CA (1) CA2533320A1 (pt)
CO (1) CO5680434A2 (pt)
CY (2) CY1112571T1 (pt)
DK (2) DK1660458T3 (pt)
EC (1) ECSP066371A (pt)
ES (2) ES2380206T3 (pt)
HK (1) HK1091813A1 (pt)
HR (2) HRP20120335T1 (pt)
IL (1) IL173129A0 (pt)
IS (1) IS2873B (pt)
MA (1) MA27994A1 (pt)
MX (1) MXPA06001759A (pt)
MY (1) MY147449A (pt)
NO (1) NO333306B1 (pt)
NZ (1) NZ585188A (pt)
PL (2) PL2287156T3 (pt)
PT (2) PT2287156E (pt)
RU (1) RU2395500C2 (pt)
SG (1) SG145749A1 (pt)
SI (2) SI2287156T1 (pt)
TN (1) TNSN06052A1 (pt)
TW (1) TWI378923B (pt)
WO (1) WO2005016894A1 (pt)
ZA (1) ZA200600464B (pt)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
PL377847A1 (pl) 2003-01-14 2006-02-20 Arena Pharmaceuticals Inc. 1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2004313181A (ja) * 2003-04-02 2004-11-11 Canon Inc 感染症起炎菌検出用プローブ及びプローブセット、ならびに担体及び遺伝子検査方法
RS53109B (en) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
AU2004264382A1 (en) * 2003-08-15 2005-02-24 Irm Llc 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
WO2005096784A2 (en) 2004-04-08 2005-10-20 Targegen, Inc. Benzotriazine inhibitors of kinases
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
EP1799656A4 (en) 2004-08-25 2009-09-02 Targegen Inc HETEROCYCLIC COMPOUNDS AND METHODS OF USE
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
DK1856135T3 (da) 2005-01-19 2010-04-12 Rigel Pharmaceuticals Inc Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser
CA2608367C (en) * 2005-06-08 2014-08-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
AR054834A1 (es) * 2005-07-15 2007-07-18 Glaxo Group Ltd Derivados de 1,1-dioxido-2,3-dihidro-1,2-benzoisotiazol-6-il-1h-indazol-4-il-2,4 pirimidina diamina
WO2007028445A1 (en) * 2005-07-15 2007-03-15 Glaxo Group Limited 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
GB0517329D0 (en) * 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
HUE028987T2 (en) 2005-11-01 2017-01-30 Targegen Inc BI-aryl-meta-pyrimidine inhibitors of kinases
TW200736232A (en) * 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
WO2007085540A1 (en) * 2006-01-27 2007-08-02 Glaxo Group Limited 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
PL1984357T3 (pl) 2006-02-17 2014-03-31 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do leczenia lub zapobiegania chorób autoimmunologicznych
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
DK2447359T3 (en) 2006-04-14 2016-02-08 Cell Signaling Technology Inc Genetic defects and mutated ALK kinase in human solid tumors
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
EP1914240B1 (en) 2006-10-11 2009-12-02 Astellas Pharma Inc. EML4-ALK fusion gene
JP5512274B2 (ja) 2006-10-23 2014-06-04 セファロン、インク． ＡＬＫ阻害剤およびｃ−ＭＥＴ阻害剤としての２，４−ジアミノピリミジンの縮合二環式誘導体
BRPI0722384A2 (pt) * 2006-12-08 2012-06-12 Irm Llc compostos inibidores de proteÍna quinase, composiÇÕes contendo os mesmos bem como seus usos
PL2091918T3 (pl) * 2006-12-08 2015-02-27 Novartis Ag Związki i kompozycje jako inhibitory kinazy białkowej
EP2099771A1 (en) * 2006-12-19 2009-09-16 Genentech, Inc. Pyrimidine kinase inhibitors
AR065015A1 (es) 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
AU2008240359B2 (en) 2007-04-18 2014-06-26 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
CA2693880A1 (en) * 2007-07-16 2009-01-22 Astrazeneca Ab Pyrimidine derivatives 934
CL2008002319A1 (es) * 2007-08-08 2009-01-02 Mithkline Beecham Corp Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
EP2190826A2 (en) * 2007-08-28 2010-06-02 Irm Llc 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
EP2234986A2 (en) 2007-12-20 2010-10-06 Cellzome Limited Sulfamides as zap-70 inhibitors
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
KR101238585B1 (ko) * 2008-04-07 2013-02-28 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EA019973B1 (ru) 2008-04-16 2014-07-30 Портола Фармасьютиклз, Инк. ИНГИБИТОРЫ Syk ПРОТЕИНКИНАЗ
WO2009136995A2 (en) 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
BRPI0908637B8 (pt) 2008-05-21 2021-05-25 Ariad Pharma Inc composto e composição farmacêutica do mesmo
KR101695501B1 (ko) * 2008-06-17 2017-01-11 아스트라제네카 아베 피리딘 화합물
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
NZ594323A (en) 2009-01-23 2013-05-31 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the jak pathway
ES2423804T3 (es) 2009-04-03 2013-09-24 Cellzome Gmbh Métodos para la identificación de moléculas que interaccionan con cinasas y para la purificación de proteínas de cinasa
EP2419423A1 (en) 2009-04-14 2012-02-22 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
CA2760794C (en) 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EP2440534A2 (en) * 2009-06-10 2012-04-18 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors
CA2764983A1 (en) * 2009-06-10 2010-12-16 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
CA2763730A1 (en) * 2009-06-18 2010-12-23 Cellzome Limited Heterocyclylaminopyrimidines as kinase inhibitors
US20120165332A1 (en) * 2009-06-18 2012-06-28 Cellzome Limited Sulfonamides and sulfamides as zap-70 inhibitors
CA2771675A1 (en) * 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
US20130137709A1 (en) * 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
WO2011144742A1 (en) 2010-05-21 2011-11-24 Chemilia Ab Novel pyrimidine derivatives
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
US8563568B2 (en) 2010-08-10 2013-10-22 Celgene Avilomics Research, Inc. Besylate salt of a BTK inhibitor
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
CA2816219C (en) 2010-11-01 2019-10-29 Portola Pharmaceuticals, Inc. Nicotinamides as syk modulators
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
EP2635557A2 (en) 2010-11-01 2013-09-11 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
CA2815858C (en) 2010-11-01 2018-10-16 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
WO2012061415A1 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
US9133224B2 (en) 2010-11-29 2015-09-15 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
ES2643016T3 (es) * 2010-12-17 2017-11-21 Novartis Ag Formas cristalinas de 5-cloro-N2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-N4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
UY33817A (es) 2010-12-21 2012-07-31 Boehringer Ingelheim Int ?nuevas oxindolpirimidinas bencílicas?.
JP2012153674A (ja) 2011-01-28 2012-08-16 Astellas Pharma Inc ジ（アリールアミノ）アリール化合物の製造方法及びその合成中間体
EP2670401B1 (en) * 2011-02-02 2015-06-10 Novartis AG Methods of using alk inhibitors
EP2675794B1 (en) 2011-02-17 2019-02-13 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
JP5937111B2 (ja) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ Ｆａｋ阻害剤
CA2830129C (en) 2011-03-24 2016-07-19 Chemilia Ab Novel pyrimidine derivatives
US9249124B2 (en) 2011-03-30 2016-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase inhibitors and methods of making and using thereof
HUE064883T2 (hu) 2011-04-22 2024-04-28 Signal Pharm Llc Szubsztituált diaminokarboxamid- és diaminokarbonitril-pirimidinek, azok készítményei és azokkal történõ kezelési eljárások
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
WO2013063401A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
AU2012340555B2 (en) 2011-11-23 2016-10-20 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
ES2570976T3 (es) 2012-03-06 2016-05-23 Cephalon Inc Derivado de 2,4-diaminopirimidina bicíclico condensado como inhibidor dual de ALK y FAK
RU2711077C9 (ru) 2012-03-15 2020-08-11 Селджен Кар Ллс Соли ингибитора киназы рецептора эпидермального фактора роста
MX356753B (es) 2012-03-15 2018-06-12 Celgene Avilomics Res Inc Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
KR101582852B1 (ko) 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
KR101446742B1 (ko) 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CA2890346A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
ES2728008T3 (es) * 2012-11-06 2019-10-21 Shanghai Fochon Pharmaceutical Co Ltd Inhibidores de quinasa ALK
CN103804299A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2945652B1 (en) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
CN105188371A (zh) 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk抑制剂及其用途
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CA2912806A1 (en) 2013-05-29 2014-12-04 Cephalon, Inc. Pyrrolotriazines as alk inhibitors
BR112015030578A2 (pt) 2013-06-18 2017-07-25 Novartis Ag combinações farmacêuticas
SG11201600055PA (en) * 2013-07-11 2016-02-26 Betta Pharmaceuticals Co Ltd Protein tyrosine kinase modulators and methods of use
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
WO2015038868A1 (en) * 2013-09-13 2015-03-19 Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivatives
RU2550346C2 (ru) 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
KR102357699B1 (ko) 2013-11-06 2022-02-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 발현 프로파일링에 의한 림프종 유형의 하위유형 분류 방법
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2015164604A1 (en) * 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) * 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
ES2741785T3 (es) 2014-08-13 2020-02-12 Celgene Car Llc Formas y composiciones de un inhibidor de ERK
WO2016029002A2 (en) * 2014-08-22 2016-02-25 Clovis Oncology, Inc. Growth factor receptor inhibitors
SI3209647T1 (sl) 2014-10-21 2021-01-29 Ariad Pharmaceuticals, Inc. Kristalinične oblike 5-kloro-N4-(-2-(dimetilfosforoil)fenil)-N2-(2-metoksi-4-(4-(4-metilpi- perazin-1-il) piperidin-1-il)pirimidin-2,4-diamina
MX2017007883A (es) 2014-12-16 2017-09-05 Signal Pharm Llc Formulaciones de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hdroxi-4-metil ciclohexilamino)-pirimidina-5-carboxamida.
EP3233808B1 (en) 2014-12-16 2021-07-14 Signal Pharmaceuticals, LLC Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
KR102595163B1 (ko) 2015-01-06 2023-10-30 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 상태의 치료 방법
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
WO2016167511A2 (ko) * 2015-04-14 2016-10-20 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR20230160955A (ko) 2015-06-22 2023-11-24 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
MX2018001004A (es) 2015-07-24 2018-06-07 Celgene Corp Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilci clohexanol e intermedios utiles en este.
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN106699743B (zh) * 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
CN106883213B (zh) * 2015-12-15 2021-04-20 合肥中科普瑞昇生物医药科技有限公司 一种egfr和alk激酶的双重抑制剂
JP2019520382A (ja) * 2016-06-27 2019-07-18 杭州雷索薬業有限公司Ｈａｎｇｚｈｏｕ Ｒｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ ベンゾフランピラゾールアミン類プロテインキナーゼ阻害薬
CA3033223A1 (en) 2016-08-29 2018-03-08 The Regents Of The University Of Michigan Aminopyrimidines as alk inhibitors
KR101876514B1 (ko) 2016-11-08 2018-07-10 한국화학연구원 신규한 피리미딘화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암 및 염증질환의 예방 또는 치료용 약학적 조성물
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
JP6728503B2 (ja) 2017-02-24 2020-07-22 テグ−キョンプク メディカル イノベーション ファウンデーション 血液脳関門を通過することができる化合物を有効成分として含有する脳腫瘍の予防または治療用薬学的組成物
JOP20190281A1 (ar) * 2017-06-13 2019-12-02 Korea Res Inst Chemical Tech مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
KR20200051684A (ko) 2017-09-07 2020-05-13 레볼루션 메디슨즈, 인크. 암 치료를 위한 shp2 억제제 조성물 및 방법
KR101992621B1 (ko) 2017-12-07 2019-09-27 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
EP3715350B1 (en) * 2017-12-21 2024-05-08 Shenzhen TargetRx, Inc. Arylphosphine oxides for inhibiting kinase activity
SG11202009443RA (en) 2018-04-05 2020-10-29 Sumitomo Dainippon Pharma Oncology Inc Axl kinase inhibitors and use of the same
WO2020076723A1 (en) 2018-10-08 2020-04-16 Revolution Medicines, Inc. Shp2 inhibitor compositions for use in treating cancer
WO2020088390A1 (zh) * 2018-10-29 2020-05-07 江苏先声药业有限公司 作为第四代egfr抑制剂的嘧啶吡唑类化合物
WO2020147702A1 (en) * 2019-01-17 2020-07-23 Betta Pharmaceuticals Co., Ltd Egfr inhibitors, compositions and methods thereof
EP3930845A1 (en) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
AU2020300619A1 (en) 2019-07-03 2022-01-27 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
US11608346B2 (en) 2019-11-04 2023-03-21 Revolution Medicines, Inc. Ras inhibitors
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
EP4054720A1 (en) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras inhibitors
US20210139517A1 (en) 2019-11-08 2021-05-13 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
JP7390487B2 (ja) * 2019-12-03 2023-12-01 サムジン ファーマシューティカル カンパニー，リミテッド 焦点接着キナーゼ阻害剤としての新規なアダマンタン誘導体
JP2023509701A (ja) 2020-01-07 2023-03-09 レヴォリューション・メディスンズ，インコーポレイテッド Ｓｈｐ２阻害剤投薬およびがんを処置する方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4110340A4 (en) * 2020-02-25 2024-08-28 Dana Farber Cancer Inst Inc POTENT AND SELECTIVE ALK DEGRADING AGENTS
KR20230042600A (ko) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
CN116457358A (zh) 2020-09-15 2023-07-18 锐新医药公司 作为ras抑制剂以治疗癌症的吲哚衍生物
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
WO2022214681A1 (en) 2021-04-09 2022-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
JP2024517845A (ja) 2021-05-05 2024-04-23 レボリューション メディシンズ インコーポレイテッド がん治療のためのｒａｓ阻害剤
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20240143136A (ko) 2023-03-23 2024-10-02 청주대학교 산학협력단 콘크리트 양생용 광발열 단열시트 및 콘크리트 구조물의 조기 시공 방법
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
US20240352036A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
US20240352038A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129020C (pt) 1964-12-15
US3432493A (en) 1966-06-27 1969-03-11 Abbott Lab Substituted sulfanilamides
US3367149A (en) * 1966-12-15 1968-02-06 Minnesota Mining & Mfg Radiant white light source
EP0002341B1 (en) * 1977-11-28 1982-01-20 Barry Boettcher Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes
JPS5964558A (ja) * 1982-09-30 1984-04-12 三菱電機株式会社 耐熱軟質複合体の製造法
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE69839735D1 (de) * 1997-12-15 2008-08-28 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
UA72458C2 (uk) * 1998-03-27 2005-03-15 Янссен Фармацевтика Н.В. Похідні піримідину, спосіб їх отримання, фармацевтична композиція на їх основі, спосіб її отримання, комбінація сполук та продукт для лікування віл
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6797706B1 (en) * 1999-06-09 2004-09-28 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclecarboxamide derivative
JP4622047B2 (ja) * 1999-06-09 2011-02-02 アステラス製薬株式会社 新規なヘテロ環カルボキサミド誘導体
ES2306671T3 (es) 1999-10-07 2008-11-16 Amgen Inc. Inhibidores de triazina quinasa.
JP2003532635A (ja) 2000-02-17 2003-11-05 アムジエン・インコーポレーテツド キナーゼ阻害薬
US6376770B1 (en) * 2000-02-28 2002-04-23 Douglas Hyde Quick connecting universal electrical box and wiring system
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US20020132823A1 (en) 2001-01-17 2002-09-19 Jiahuai Han Assay method
JP4510442B2 (ja) * 2001-06-26 2010-07-21 ブリストル−マイヤーズ スクイブ カンパニー ＴＮＦ−α発現のＮ−ヘテロ環インヒビター
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
CN100436427C (zh) * 2001-11-01 2008-11-26 詹森药业有限公司 用作糖原合酶激酶3β抑制剂的氨基苯甲酰胺衍生物
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003209077A1 (en) 2002-02-08 2003-09-02 Smithkline Beecham Corporation Pyrimidine compounds
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
CA2490888C (en) * 2002-06-28 2011-05-24 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxamide derivative
ES2445208T3 (es) * 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
AU2004210081B2 (en) * 2003-02-07 2009-11-26 Janssen Pharmaceutica N.V. Pyrimidine derivatives for the prevention of HIV infection
DE602004021472D1 (en) * 2003-02-20 2009-07-23 Smithkline Beecham Corp Pyrimiidinverbindungen
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
DE602004008303T2 (de) * 2003-07-16 2008-05-08 Janssen Pharmaceutica N.V. Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE602004017654D1 (de) * 2003-07-16 2008-12-18 Janssen Pharmaceutica Nv Triazolopyrimidin derivate als inhibitoren von glycogen synthase kinase-3
WO2005013996A2 (en) * 2003-08-07 2005-02-17 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
AU2004264382A1 (en) * 2003-08-15 2005-02-24 Irm Llc 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
MXPA06003054A (es) 2003-09-18 2006-05-31 Novartis Ag 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos.
CA2584295C (en) 2004-11-24 2014-08-26 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses

Also Published As

Publication number Publication date
EP1660458A1 (en) 2006-05-31
ZA200600464B (en) 2006-12-27
IL173129A0 (en) 2006-06-11
CA2533320A1 (en) 2006-02-24
MY147449A (en) 2012-12-14
DK2287156T3 (da) 2013-08-26
SI2287156T1 (sl) 2013-09-30
CO5680434A2 (es) 2006-09-29
AR045458A1 (es) 2005-10-26
PL2287156T3 (pl) 2013-11-29
AU2004264382A1 (en) 2005-02-24
PT2287156E (pt) 2013-08-26
IS8349A (is) 2006-03-13
BRPI0413616A (pt) 2006-10-17
HRP20130724T1 (hr) 2013-10-11
NZ585188A (en) 2011-09-30
SG145749A1 (en) 2008-09-29
US20080132504A1 (en) 2008-06-05
RU2395500C2 (ru) 2010-07-27
EP1660458B1 (en) 2012-01-25
JP2010241830A (ja) 2010-10-28
JP4607879B2 (ja) 2011-01-05
BRPI0413616B1 (pt) 2020-04-28
ES2380206T3 (es) 2012-05-09
SI1660458T1 (sl) 2012-05-31
RU2006107785A (ru) 2007-09-20
AU2008229685A1 (en) 2008-10-30
IS2873B (is) 2014-03-15
US20110098280A1 (en) 2011-04-28
KR20060039938A (ko) 2006-05-09
NO20061214L (no) 2006-05-15
EP2287156A1 (en) 2011-02-23
BR122019017579B8 (pt) 2021-07-27
TW200526598A (en) 2005-08-16
MA27994A1 (fr) 2006-07-03
TWI378923B (en) 2012-12-11
BR122019017579B1 (pt) 2020-08-11
WO2005016894A1 (en) 2005-02-24
PT1660458E (pt) 2012-04-27
US7893074B2 (en) 2011-02-22
PL1660458T3 (pl) 2012-07-31
EP2287156B1 (en) 2013-05-29
ATE542801T1 (de) 2012-02-15
NO333306B1 (no) 2013-04-29
ES2424881T3 (es) 2013-10-09
TNSN06052A1 (en) 2007-10-03
AU2008229685B2 (en) 2011-07-28
JP2007502260A (ja) 2007-02-08
KR100904570B1 (ko) 2009-06-25
CY1117015T1 (el) 2017-04-05
ECSP066371A (es) 2006-08-30
CY1112571T1 (el) 2016-02-10
HRP20120335T1 (hr) 2012-05-31
MXPA06001759A (es) 2006-05-12
DK1660458T3 (da) 2012-05-07
HK1091813A1 (en) 2007-01-26

Similar Documents

Publication Publication Date Title
BRPI0413616B8 (pt) 2,4-pirimidinadiaminas, seus usos, e composição farmacêutica
NO20040547L (no) Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse.
BRPI0513811A (pt) imidazo [4,5-d] pirimidinas, seus usos e processos de preparação
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
NO20071703L (no) Kinazolinderivater
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
BRPI0821115A8 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
EA200701296A1 (ru) 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства
BR112012010124A2 (pt) composto, uso de um animal composto, derivado de cromenona, e, método para o tratamento ou prevenção de um animal de sangue quente tendo tumores que são sensíveis á inibição das enzimas de pi 3-cinase
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
NO20054414L (no) Dihydropteridinoner, metoder for deres fremstilling og bruk av disse som medisiner
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
NO20070061L (no) 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav
BRPI0511874A (pt) derivados da pirrolopiridina
EA201590066A1 (ru) Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1
BR112021026820A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl)
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
SE0300456D0 (sv) Novel compounds
NO20090067L (no) Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
BRPI0416674A (pt) tiazolidinona amidas, amidas de ácido tiazolidino carboxìlico, processos de fabricação, e uso das mesmas
BR112016007430A2 (pt) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas
DK1183247T3 (da) Polycycliske thiazolsystemer, fremgangsmåde til fremstilling heraf og lægemidler indeholdende disse forbindelser
NO20021337D0 (no) 4-benzylaminoquinolinkonjugater med gallesyre og deres heteroanaloger, fremgangsmåte for deres fremstilling, legemidlersom inneholder disse forbindelser og deres anvendelse

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH) , NOVARTIS INTERNATIONAL PHARMACE

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF